Genta Announces The Company Will Appeal FDA Action On New Drug Application Of Genasense(R) In Chronic Lymphocytic Leukemia

... Genta Incorporated (Nasdaq: GNTA) today announced that the Company will appeal the non-approvable notice from the Food and Drug Administration's (FDA) Office of Oncology Drug Products of its New Drug Application (NDA) for the use of Genasense(R) (oblimersen sodium) Injection plus chemotherapy in patients with chronic lymphocytic leukemia (CLL). [click link for full article] ...